Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing small-molecule therapies for retinal disease. The KPRX news feed highlights company announcements on its development pipeline, clinical trial progress, strategic partnerships, and intellectual property related to its lead programs KIO-301 and KIO-104.
Recent news releases describe ongoing Phase 2 clinical trials for retinal diseases. The ABACUS-2 trial evaluates KIO-301, a molecular photoswitch being developed for vision restoration in patients with retinitis pigmentosa, with plans to expand into choroideremia and Stargardt disease. The KLARITY study investigates KIO-104, a non-steroidal, immuno-modulatory DHODH inhibitor, in patients with retinal inflammation and macular edema across several inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema.
Investors following KPRX news can review quarterly financial updates, as Kiora reports research and development spending, collaboration credits, and cash position alongside clinical development updates. Press releases also cover collaboration agreements, such as the exclusive co-development and commercialization relationship with Théa Open Innovation for KIO-301 outside Asia and the option agreement with Senju Pharmaceutical for key Asian markets.
The news stream further includes information on new U.S. patents that expand protection for KIO-104 and the KIO-100 family of compounds, as well as Kiora’s participation in initiatives like the RARE-X Vision Consortium for rare ocular disorders. For those tracking the KPRX stock and the company’s retinal disease programs, this page aggregates Kiora’s official news, conference participation announcements, and other disclosures in one place.
Kiora Pharmaceuticals (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 p.m. ET.
A live webcast will be available on the company's investor relations website ir.kiorapharma.com, with a replay accessible for approximately 90 days.
Kiora Pharmaceuticals (NASDAQ: KPRX) appointed retina specialist Dr. Taiji Sakamoto to its Scientific Advisory Board on January 27, 2026. Dr. Sakamoto, chair of ophthalmology at Kagoshima University, will advise on clinical and scientific strategy for retinal therapeutics including non-steroidal approaches such as KIO-104. He has led research in diabetic retinopathy, retinal surgery, ocular angiogenesis, published over 460 peer-reviewed papers and held leadership roles in JRVS and international ophthalmology organizations.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced that the U.S. Patent and Trademark Office issued U.S. patent US-12,472,263 on December 1, 2025 covering additional, novel formulations of the KIO-100 family, including a specific formulation of the API in KIO-104.
The API in KIO-104 is a non-steroidal DHODH inhibitor formulated for local retinal delivery. The company is actively screening and dosing in the multicenter Phase 2 KLARITY trial, enrolling up to 28 patients across retinal inflammatory conditions including posterior non-infectious uveitis and diabetic macular edema. KIO-104 previously demonstrated clinical proof-of-concept in a Phase 1 trial in non-infectious uveitis.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported third quarter 2025 results and clinical updates on two Phase 2 retinal trials. The company ended the quarter with $19.4 million in cash, cash equivalents and short-term investments, plus $1.2 million collaboration receivables and $1.5 million tax and research credit receivables.
Kiora said it continues to recruit and dose patients in KLARITY (KIO-104, retinal inflammation) and ABACUS-2 (KIO-301, retinitis pigmentosa). R&D expense was $2.7 million in Q3 2025 (partially offset by $1.7 million reimbursable expenses from Théa) versus $2.1 million in Q3 2024. The company reported net income $27 thousand for Q3 2025 versus a net loss of $3.4 million in Q3 2024 and expects cash runway into late 2027.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced on October 30, 2025 that it joined Global Genes' RARE-X Vision Consortium, a corporate‑nonprofit collaboration to accelerate research and development of therapies for rare ocular disorders.
The consortium will build a de‑identified, individual‑level global data repository to support patient identification and recruitment, define meaningful outcome measures by aggregating functional, structural, and patient‑reported data, and promote inclusive study design with patient input. Kiora's CEO, Brian Strem, said the collaboration aims to increase the probability of advancing Kiora's experimental inherited retinal disease therapy toward patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends. Maxim Growth Summit in New York: Brian M. Strem, PhD, President and CEO, will speak on an ophthalmology panel titled "A vision of innovation" on October 22, 2025 at 3:00 PM EDT (panel overview link: maximgrp.com/2025-growth-summit).
Eyecelerator @ AAO 2025 in Orlando: Eric Daniels, MD, MBA, Chief Development Officer, will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT (program link: eyecelerator.com/aao-2025-program).
Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2025 financial results and pipeline updates for retinal disease treatments. The company initiated two Phase 2 clinical trials: KLARITY for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa). Kiora secured a potential $110M partnership with Senju Pharmaceutical for KIO-301 development in Asia.
Financial highlights include a $20.7M cash position, with additional $2.4M in collaboration receivables and $0.7M in tax credits. The company reported a net loss of $2.2M in Q2 2025, unchanged from Q2 2024. R&D expenses increased to $2.6M (before $1.7M in reimbursements), while G&A expenses decreased to $1.4M. Cash runway extends into late 2027, beyond anticipated clinical trial readouts.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. President and CEO Brian M. Strem, Ph.D. will present the company's pipeline of therapies focused on inherited and inflammatory retinal diseases.
The presentation is scheduled for Wednesday, August 13, 2025, at 7:00 am EDT. Investors can access the presentation through Kiora's investor relations website, with the replay remaining available for 90 days following the event.
Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.
From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.
As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.